Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 752

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 752
---
 gain or loss recognized in the statement of operations. On October 9, 2024, the Company entered into the October SPA, with certain accredited investors and agreed to issue and sell to the investors, in a private placement offering, (i) 806,452Company Common Shares, and (ii) common share purchase warrants, or the Common Warrants, to purchase 806,452Company Common Shares, at a combined purchase price of $ 3.97, for aggregate gross proceeds of $ 3.2million. The Common Warrants have a term of fiveyears and have an exercise price of $ 4.25per share. Pursuant to the October SPA, the Company agreed to grant the investors the right to participate, in the aggregate, in up to fifty percent ( 50%) of future offerings for one yearfollowing the closing of the offering. In addition, the Company agreed not to enter into an equity line of credit or similar agreement, without the consent of the majority of the holders of the preferred shares. The transactions contemplated by the October SPA closed on October 10, 2024. On June 28, 2024, the Company entered into a securities purchase agreement for the issuance of 81,944Company Common Shares at a purchase price of $ 9.60per share. The offering closed on July 1, 2024. Investors also received unregistered warrants to purchase up to 81,944Company Common Shares at an exercise price of $ 9.60per share. These warrants are exercisable upon issuance and will expire five years from the date of issuance. The offering resulted in gross proceeds of $ 786,660. The net proceeds were used for working capital and general corporate purposes. H.C. Wainwright & Co., LLC served as the exclusive placement agent for the offering, or the Placement Agent. The Company agreed to pay the Placement Agent a cash fee of 7.0% of the gross proceeds, a management fee of 1.0% of the gross proceeds, and $ 50,000for accountable expenses. Additionally, the Company issued to the Placement Agent warrants to purchase up to 5,736Company Common Shares at an exercise price of $ 12.00per share. These warrants are exercisable from the date of issuance until five years from the commencement of sales in the offering. On March 20, 2024, the Company entered into a securities purchase agreement, or the Purchase Agreement, providing for the issuance in a registered direct offering